SHRI BIREN SINGH ENGTI; Sir, as I said earlier in my statement, in the Seventh Five Year Plan, we iwve a total of Rs. 163 crores for the Spates and the Union Territories. All the Staet Governments and the Union Territories have their component in their State Plan regarding the research and development. They are doing it. *(Interruption)*

MR. CHAIRMAN: He is referring about the backward States.

SHRI BIREN SINGH ENGTI; All the States, Sir.

श्री कैलाश पति मिश्र : सभापति जी, मुझे उत्तर प्राप्त नहीं हुआ है ।

श्री सभापति : आपके प्रश्न का उन्होंने उत्तर दिया है कि प्रयास कर रहे हैं ।

श्री कैलाश पति मिश्र : महोदय, रिप्लाई नहीं आया है । राज्यों में जो अन्तर आ गया है वह आगे बढ़े हुए राज्यों से कुछ राज्य बहुत पीछे छूट गये हैं (**व्यवधान**)

श्री चतुरानन मिश्र : वो बैकवर्ड स्टेट्स को उठाने के लिये प्रयास कर रहे हैं और यह उत्तर के लिये प्रयास कर रहे हैं ।

SHRI MADHAVSINH SOLANKI: Sir, efforts are made to deevlop science and technology in all States and most of the States have already established their departments of science and technology. Where the States are back, ward and need help, the Government would surely consider.

Drugs cleared for marketing

244. DR. (SHRIMATI) SAROJINI MAHISHI: Will the Minister of HEALTH AND FAMILY WELFARE j be pleased to state:

(a) the names of the drugs cleared for marketing in the country from lst January to :31st October, 1988;

(b) what were the forms of formulations and strengths under which these were allowed;

(c) what were the indications for which each drug had been allowed for marketing;

(d) what were the contra-indica tions of each and what precautions had been suggested;

(e) whether it is a fact that package-insert is not provided along with the medicines; and

(f) if so, what action had been taken in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (KUMARI SAROJ KHAPARDE): (a) to (d) The names of drugs approved for marketing under Rule 30A of the Drugs and Cosmetics Rules for the period from lat January, 1988 to 31st October. 1983 along with other required informtaion are at Annexure. *(See* Appendix CXLVIII, Annexure No. 93) and State. ment *(See* below.)

(e) and *d)* While leading manufacturers generally give package inserts, the're is no specific provision in 'he Drugs and Cosmetics Rules for such inserts. However, all prescription medicines carry a warning on label and cartons that the medicines are required to be sold on the prescription of a Registered Medical Practitioner only.

Statement

SI. No	Name of t lie drug	Contra-indications/precautions to be observed
1	2	3
I	Etoposide Caps/Inj	To be administered only in life threatening concfition. Contra-indicated in acute infections. Blood count to be monitored. Contra-indicated in pregnant women.
2	BezafibrateTabs.	. Drug to be withdrawn if not tolerated.
3	Aroineptine Tabs.	To be used with caution in patients with impiired liver function and other organic disease>.
4	Astemaole Tabs.	Avoid administration alon$_t$; with C.N.S. depresents.
5	Budesontde Inhaler	To avoid administration in non-steroid dependent asthma.
6	Penfluridol Tabs.	Caution in pat'snts und.r the influence ol" C.N.S. dapresents' and in parents with Done marrow c epression.
7	Aclarubicin Inj.	Contra-indicated in acute infections. Blood count to be monitored. Con tr>-indie;'ted in pregnant women.
8	Zidovudine Cips.	Ore shouid be taken in patients suffering from organic disease.
9	Ceftriaxone Sodium injection	Administer with great care in patients allergic to Pencillin.
10	Minoxidil Topical Lotion	Minoxidil is contra-indicated in ph.eoclvomocytoma.
11	Berizydamine Topic il cream	No special contra-indication.
12	Interferon alpha 28 injection	Contra-indicated in bone marrow insufficiency.
13	Melagenina Lotion	No special contra-indication.
14	Amri non J Inj.	To be withdrawn if not tolerated. Guard against thrombocytopenia and fever.
15	Ethamsylate Tabs.	High molecular plasma expanders should not be given before ethamoylate.
16	Minocycline Tabs./Ops./Oral/Sus.	Reduce dose if there is history of renal impairment.
17	Alprazolam Tabs.	Have dependence potential.
18	Cefuroximc Inj. .	Administer with gre it care in patients allergic to penicilline.
19	Terlatotol Hcl Tabs.	It should be avoided if there is metabolic disease.

1	2	3
20	Cyclosporin Ora! soIution'Inj.'O	ips. Contra-indicated in bone marrow depression and acute infection.
21	C ftazidima Pentahydrate rnj.	Administer with great care in petients sllergic to Pencillin©.
22	Gemfib.ozilCaps.	Drug to be withdrawn if not tolerateu.
23	Trichabendazol *(Vet.)* Bolus & Suspension.	Contra-ind/'cated in pregnancy.

DR. (SHRIMATI) SAROJINI MAHISHI.- Sir, the Minister has said that there is no specific mention in rule 33 of the Drugs and Cosmetics Rules that there should be special mention of the side-effects, the harmful effects, the contra-indications, tha Precautionary measures, etc, but, how-ever, the Registered Medical Practitioners will take all these into consideration. Sir, there are many drugs which have been banned by other countries. For example, even Anal gy n, the brand name of which is Noval gyn. which is banned by more than 70 countries is being sold in Indfa as one of the common drugs. There are ilso other drugs like Oxycanal Butazcne and Cynyl Butazone which are very harmful. If a person who is addicted to drinking takes certain traquillizers, the next day he will not be in this world. Therefore, I would like to mention that the package inserts should consist of these things also an-1 along with indications. ingredients, date of expirv, etc.. these things should also be made compulsory under -ule 33. Precautionary measures contra-indications and harmful effects of drugs also should be mentioned. There are manv people who to self-medication Therefore, T would like to know whether the Government is going fo take it seriously and make it part of rule 33-J that it shouid be mentioned necessarily and be part of the package instrt. *(Interruptions)*

KUMARI SAROJ KHAPARDE: Whatever suggestions have been given by the hon. Member are really welcome by the Government and by all of us. I would like to mention -le^e the difficulties in inserting the information on all d'rugs. Firstly, there is no provision in the Drugs and Cosmetics Act and the Rules to compel a drug manufacturer to give the pack, age insert. Secondly, (Interruptions) . . in our country, nil the information given in the package insert is difficult to be printed on a small label or strip. Thirdly, insertion of ihe package insert may increase the cost of the medicine, particularly ir India, when such... (Interruptions'

MR. CHAIRMAN: Please, let her reply. *(Interruptions)*

KUMARI SAROJ KHAPARDE: Sir, these are the difficulties in inserting all these things in a package in a carton. However, the suggestions given by hon. Members in this regard are welcome and will be taken care of. We will try to implement any suggestion that is possible of implementation.

MR. CHAIRMAN: Question Hour is over.